sglt2 inhibitors vs glp-1 agonists Cardiorenal Protection: Potential of and Receptor in the Treatment of Type 2 Diabetes | Diabetes Therapy GLP-1RAs and SGLT2 Inhibitors Show
Description
The FDA has warned against unapproved compounded GLP-1 drugs, highlighting risks like dosing errors and contamination
Incidents related to aspiration or regurgitation of gastric contents after appropriate fasting, can be reported to the Canada Vigilance Program at or to ISMP Canada through the Individual Practitioner Reporting portal at The Canadian Medication Incident Reporting and Prevention System (CMIRPS) is a collaborative pan-Canadian program of Health Canada, the Canadian Institute for Health Information (CIHI), the Institute for Safe Medication Practices Canada (ISMP Canada) and Healthcare Excellence Canada (HEC)
Protein intake and lean mass Preserving muscle should be a priority, not an afterthought
doi: 10.2337/diabetes.52.1.102 [DOI] [PubMed] [Google Scholar] 125
A similar increased risk for heart failure was also observed for alogliptin (3.9% vs 3.3% for placebo)
( [Google Scholar] 14.Cummins E The Future of Weight Loss Looks a Lot Like Its Past
